ClinicalTrials.gg
Status unknownNCT02059616Updated Apr 30, 2014

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

A Phase 2 interventional study of Amlodipine 5mg and Amlodipine 10mg in Essential Hypertension, sponsored by HK inno.N Corporation. Status unknown at 20 sites in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-30.

Sponsored by HK inno.N Corporation · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
384
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing amlodipine in Essential Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Amlodipine · Essential Hypertension.

Planned enrollment
12th of 34
384 · median 314
Started
2014
with 6 others
Phase 2
4 of 34
none open now
Registered
14th of 34
by date
Lead sponsor
3 of 34
HK inno.N Corporation

Among the 34 studies testing amlodipine in Essential Hypertension, this one is the 12th largest by planned enrollment, is one of 7 that started in 2014, is one of 4 in phase 2, and was the 14th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 34 studies testing amlodipine in Essential Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing amlodipine in Essential Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

03

Conditions studied

  • Essential Hypertension
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥ 19 and ≤ 75 years old
  • Subject with mild-to-moderate uncomplicated essential hypertension
  • Subject who have voluntarily agreed to participate in the trial and signed the written form, after having listened to the purpose, method, and effect of the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Subject with severe hypertension (siDBP ≥ 115 mmHg or siSBP ≥ 185 mmHg)
  • Subject with difference in the mean blood pressure of over 10mmHg for siDBP or 20mmHg for siSBP between both arms at the screening visit
  • Subject with known or suspected secondary hypertension [including but not limited to any of the following: renovascular hypertension, adrenal medullary and cortical hyperfunction, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.]
  • Subject with symptomatic orthostatic hypotension (a sudden fall in siDBP of at least 10 mmHg or siSBP of at least 20 mmHg after standing compared with blood pressure from the sitting or supine position)
  • Subject with Type 1 diabetes mellitus OR Type 2 diabetes mellitus with poor glucose control (defined as subject on insulin treatment, with > 9.0%, or with a modification in the oral anti-hyperglycemic medication regiment within the past 12 weeks prior to Visit 1)
  • Subject with severe heart disease (Congestive heart failure ( Class III-IV), ischemic heart disease within the past 6 months (unstable angina, myocardial infarction), peripheral vascular disease, history of Percutaneous Transluminal Coronary Angioplasty or Coronary Artery Bypass Grafting)
  • Subject with ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically significant arrhythmia
  • Subject with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, haemodynamically relevant stenosis of the aortic or mitral valve
  • Subject with severe cerebrovascular disease (history of stroke, cerebral infarction, or cerebral hemorrhage within the past 6 months)
  • Subject with or with a history of wasting disease, diseases (rheumatoid arthritis, systemic lupus erythematosus), or connective tissue disease
  • Subject with known moderate or malignant retinopathy (history of retinal signs of hemorrhage, visual impairment, retinal microaneurysm, etc. within the past 6 months)
  • Subject with the following clinically significant laboratory abnormalities:

    • or ALT > 3 x Upper Limit Normal ()
    • Serum Creatinine > 1.5 ULN
    • Serum potassium \< 3.5 mmol/L or > 5.5 mmol/L
  • Subject with any surgical or medical condition of the gastrointestinal tract that might significantly alter the absorption, distribution, metabolism or excretion of the drug
  • Subject with a history of malignant tumors including leukemia and lymphoma within the past 5 years (except for localized basal cell carcinoma of the skin)
  • Subject with any chronic inflammatory condition needing chronic anti-inflammatory therapy
  • Subject with chronic kidney disease on dialysis
  • Subject with cardiogenic shock
  • Subject requiring concomitant use of other antihypertensive or drugs during the entire study period
  • Subject with known or suspected contraindications, including history of allergy or to ARB or dihydropyridine derivatives
  • Subject who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARB
  • Pregnant women, lactating mothers, women suspected of being pregnant, women who wish to be pregnant during the study, or women of who are not using medically acceptable methods of (oral contraceptive, intra-uterine device, condom, etc.), except for women with surgical sterilization. Pre-menopausal women who are not surgically sterilized must have a negative pregnancy test result at Visit 1 and maintain acceptable methods of contraception throughout the study. Periodic abstinence (eg, symptothermal, calendar, post-ovulation methods), or hormonal contraceptive are not acceptable methods of contraception
  • History of drug or alcohol abuse within the past 1 year
  • Use of other products within the past 4 weeks
  • Subject who are judged unsuitable to participate in the study in the opinion of the investigator
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
384 participants (estimated)

Study arms

  • Experimental
    AML 5mg

    Amlodipine 5 mg, once a day for 8 weeks

    Drug: Amlodipine 5mg

  • Experimental
    AML 10mg

    Amlodipine 10 mg, once a day for 8 weeks

    Drug: Amlodipine 10mg

  • Experimental
    CC 8mg

    Candesartan Cilexetil 8 mg, once a day for 8 weeks

    Drug: Candesartan Cilexetil 8mg

  • Experimental
    CC 16mg

    Candesartan Cilexetil 16 mg, once a day for 8 weeks

    Drug: Candesartan cilexetil 16mg

  • Experimental
    AML 5mg/CC 8mg

    Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks

    Drug: Amlodipine 5mg · Drug: Candesartan Cilexetil 8mg

  • Experimental
    AML 5mg/CC16mg

    Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks

    Drug: Amlodipine 5mg · Drug: Candesartan cilexetil 16mg

  • Experimental
    AML 10mg/CC 8mg

    Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks

    Drug: Amlodipine 10mg · Drug: Candesartan Cilexetil 8mg

  • Experimental
    AML 10mg/CC 16mg

    Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks

    Drug: Amlodipine 10mg · Drug: Candesartan cilexetil 16mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline

    Time frame: Week 8

Secondary outcomes

  1. Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8

    Time frame: Week 4 and 8

  2. Change in siDBP at week 4

    Time frame: Week 4

  3. Proportion of patients achieving ΔsiDBP > 10 mmHg and ΔsiSBP < 20 mmHg after 8 weeks

    Time frame: Week 8

  4. Proportion of patients achieving siDBP < 90 mmHg and siSBP < 120 mmHg after 8 weeks

    Time frame: Week 8

07

Study locations

20 of 20 sites recruiting
  • Seoul National University Bundang Hospital
    Bundang, Korea, Republic of
    Recruiting
  • Dong-A University Hospital
    Busan, Korea, Republic of
    Recruiting
  • Yeungnam University Medical Center
    Daegu, Korea, Republic of
    Recruiting
  • Konyang University Hospital
    Daejeon, Korea, Republic of
    Recruiting
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
    Recruiting
  • Inje University Ilsan Paik Hospital
    Ilsan, Korea, Republic of
    Recruiting
  • Inha University Hospital
    Incheon, Korea, Republic of
    Recruiting
  • Hallym University Sacred Heart hospital
    Kyungki-do, Korea, Republic of
    Recruiting
  • Inje University Haeundae Baik Hospital
    Pusan, Korea, Republic of
    Recruiting
  • Pusan National University Hospital
    Pusan, Korea, Republic of
    Recruiting
  • Asan Medical Center
    Seoul, Korea, Republic of
    Recruiting
  • Ewha Womans University Mokdong Hospital
    Seoul, Korea, Republic of
    Recruiting
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
    Recruiting
  • Seoul Medical Center
    Seoul, Korea, Republic of
    Recruiting
  • Seoul St. Mary's hospital
    Seoul, Korea, Republic of
    Recruiting
  • Severance Hospital
    Seoul, Korea, Republic of
    Recruiting
  • Soonchunhyang University Hospital
    Seoul, Korea, Republic of
    Recruiting
  • Yonsei University Gangnam Severance Hospital
    Seoul, Korea, Republic of
    Recruiting
  • Ajou University Hospital
    Suwon, Korea, Republic of
    Recruiting
    • Seung-Jea Tahk · Principal investigator
  • Wonju Severance Christian Hospital
    Wonju, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Jun 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2014
First posted
Feb 11, 2014
Start
Feb 2014
Primary completionEst.
Jun 2015
CompletionEst.
Dec 2015
Last update
Apr 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02059616
Responsible party
Sponsor
First posted
Feb 11, 2014
Start date
Feb 2014
Primary completion
Jun 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Apr 30, 2014

Study contacts

Geun Seog Song, PhD
Contact
kssong1212@cj.net
82-2-6740-2440
Eun Ji Kim
Contact
keunji@cj.net
82-2-6740-2443
Seung-Jea Tahk
principal investigator · Ajou University School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amlodipine · Candesartan cilexetil

Start the discussion